The use of recombinant factor VIIa as a haemostatic agent in ICU patients
Применение рекомбинантного фактора VIIa в качестве гемостатического средства у пациентов отделения интенсивной терапии
2004-01-01
SCID: 54.1/ws6dtbve
Discuss with AI
ICU patientscoagulopathyhaemostatic agentintraoperative bleedingrecombinant factor VIIa
Figures from the paper
Abstract (AI)
Recombinant factor VIIa (rFVIIa) is a prohaemostatic agent that has successfully been used for the treatment of patients with haematological malignancies and coagulopathy. It also has been used in postsurgical patients where the coagulopathy in combination with hypothermia and metabolic acidosis causes an increase of mortality early post operation. Recently reported has been the use of rFVIIa in patients with a normal coagulation system, undergoing major surgery in order to reduce the intraoperative bleeding and the need for transfusions. Here we present our experience on rFVIIa use in ICU patients.
Key Findings
1
In postsurgical patients, rFVIIa has been used when coagulopathy combined with hypothermia and metabolic acidosis increases early postoperative mortality.
2
Recent applications include rFVIIa in patients with normal coagulation undergoing major surgery to reduce intraoperative bleeding and transfusion requirements.
3
Recombinant factor VIIa is described as a prohaemostatic agent successfully used in patients with haematological malignancies and coagulopathy.
4
The paper presents the authors’ experience using recombinant factor VIIa in intensive care unit patients.
Research Object
ICU patients receiving recombinant factor VIIa (rFVIIa) as a haemostatic agent
Research Subject
The clinical use and haemostatic effectiveness of rFVIIa, including its effects on bleeding and transfusion requirements
Publication Details
Publication Date
2004-01-01
Journal
Publisher
ISSN
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest